Cargando…
Biomarkers of Hypercoagulability in COVID-19
Autor principal: | Wada, Hideo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219011/ https://www.ncbi.nlm.nih.gov/pubmed/37240631 http://dx.doi.org/10.3390/jcm12103525 |
Ejemplares similares
-
Hypercoagulability and Anticoagulation in Patients With COVID-19 Requiring Renal Replacement Therapy
por: Roberts, Lara N., et al.
Publicado: (2020) -
Hypercoagulation in COPD: the clot thickens
por: Rahaghi, Farbod N., et al.
Publicado: (2021) -
Inflammatory and Hypercoagulable Biomarkers and Clinical Outcomes in COVID-19 Patients
por: Kitakata, Hiroki, et al.
Publicado: (2021) -
The Burden of Hypercoagulability in COVID-19
por: Kim, Madeleine, et al.
Publicado: (2022) -
Thromboinflammation and the hypercoagulability of COVID‐19
por: Connors, Jean M., et al.
Publicado: (2020)